Back to Catalog
Life Biosciences
lifebio
First FDA cleared partial epigenetic reprogramming therapy in human trials.
Total Funding
$237M
sector:biotech
stage:series_c_plus
longevity
epigenetic-reprogramming
gene-therapy
ophthalmology
cellular-rejuvenation
AAV-vector
Full Profile Gated
Register as a Qualified Purchaser to access the full profile of Life Biosciences, including financial analysis, competitive landscape, and investment thesis.